Clinical Trial Update: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating cadonilimab plus fruquintinib and paclitaxel-albumin as second-line therapy for advanced gastric/gastroesophageal junctio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Cadonilimab
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Fudan University | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING